EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development and validation of real-time recombinase polymerase amplification-based assays for detecting HPV16 and HPV18 DNA

Jiaxu Ying iD, Lingjing Mao, Yujing Tang, Meriem Fassatoui, Wei Song, Xiaosheng Xu, Xiaojian Tang, Jing Li, Hua Liu, Fangfang Jian, Qinwen Du, Gary Wong iD und 2 weitere

Microbiology Spectrum · 12.12.2023 · 11 (6)

DOI: 10.1128/spectrum.01207-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 12.12.2023. Verfasst von Jiaxu Ying und 13 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Microbes, Development and Health, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Unit of Discovery and Molecular Characterizat…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Science and Technology Major Project, Shanghai International Science and Technology Cooperation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical cancer is the fourth leading cause of cancer-related death among women worldwide. Persistent human papillomavirus (HPV) infection is the principal cause of cervical cancer, with HPV16 and HPV18 accounting for about 70% of cases worldwide. Cervical screening is an effective secondary measure for preventing cervical cancer. Testing for HPV DNA is becoming increasingly important in cervical cancer screening. The existing PCR-based HPV detection technology has several disadvantages: the assays are time-consuming, and sophisticated equipment is required to control the temperature cycles. These drawbacks have led to the development of detection technologies based on isothermal amplification. Here, we present real-time recombinase polymerase amplification (RPA-exo)-based assays for single genotyping of either the E7 or the L1 segment of HPV16 or HPV18. These assays were highly sensitive, able to detect HPV in all clinical samples with Ct values below 34, and yielded results within 25 min. A dual-detection system capable of detecting both HPV16 and HPV18 in a single reaction was also developed based on the L1 gene. It has a limit of detection of approximately 10,000 copies of each genotype per reaction. The assays were validated with DNA extracted from 36 biopsy specimens and 42 exfoliated cell samples from 43 patients with cervical lesions at different stages. The RPA-exo system is a promising clinical detection platform with the advantages of yielding results rapidly and operating at a constant temperature, while being cost-effective and easy to use. IMPORTANCE HPV DNA screening is an effective approach for the prevention of cervical cancer. The novel real-time recombinase polymerase amplification-based HPV detection systems we developed constitute an improvement over the HPV detection methods currently used in clinical practice and should help to extend cervical cancer screening in the future, particularly in point-of-care test settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsPapillomavirus InfectionsFemaleHumansHuman papillomavirus 16Human papillomavirus 18RecombinasesEarly Detection of CancerDNA, Viral

Stichwörter der Autor:innen

cervical cancerhuman papillomavirusreal-time recombinase polymerase amplification

Substanzen

RecombinasesDNA, Viral

Autor:innen und Institutionen

  • Centre for Microbes, Development and Health, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Unit of Discovery and Molecular Characterization of Pathogens , Shanghai, China.
  • Viral Hemorrhagic Fevers Research Unit, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences , Shanghai, China.
  • University of the Chinese Academy of Sciences , Beijing, China.
  • Department of Obstetrics and Gynecology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, China.
  • Institut Pasteur, Université Paris-Cite, Unité Environnement et Risque Infectieux, Cellule d'Intervention Biologique d'Urgence , Paris, France.
  • Institut Pasteur, Université Paris-cite, Unité Epidémiologie et Physiopathologie des Virus Oncogènes , Paris, France.

ORCID-Profile: Jiaxu Ying, Gary Wong, Weiwei Feng

Förderung

  • Shanghai Municipal Science and Technology Major Project
  • Shanghai International Science and Technology Cooperation Program

Zitieren

APA

Ying, J., Mao, L., Tang, Y., Fassatoui, M., Song, W., Xu, X., Tang, X., Li, J., Liu, H., Jian, F., Du, Q., Wong, G., Feng, W., & Berthet, N. (2023). Development and validation of real-time recombinase polymerase amplification-based assays for detecting HPV16 and HPV18 DNA. Microbiology Spectrum, 11(6). https://doi.org/10.1128/spectrum.01207-23

Vancouver

Ying J, Mao L, Tang Y, Fassatoui M, Song W, Xu X, et al. Development and validation of real-time recombinase polymerase amplification-based assays for detecting HPV16 and HPV18 DNA. Microbiology Spectrum. 2023;11(6). doi:10.1128/spectrum.01207-23

BibTeX
@article{Ying2023,
  author = {Ying, Jiaxu and Mao, Lingjing and Tang, Yujing and Fassatoui, Meriem and Song, Wei and Xu, Xiaosheng and Tang, Xiaojian and Li, Jing and Liu, Hua and Jian, Fangfang and Du, Qinwen and Wong, Gary and Feng, Weiwei and Berthet, Nicolas},
  title = {Development and validation of real-time recombinase polymerase amplification-based assays for detecting HPV16 and HPV18 DNA},
  journal = {Microbiology Spectrum},
  year = {2023},
  volume = {11},
  number = {6},
  doi = {10.1128/spectrum.01207-23}
}
Kostenlos starten →